Improvement of pseudophakic cystoid macular edema with subconjunctival injections of interferon α2b:a case report

Benitah, 2010, Pseudophakic cystoid macular edema, Int Ophthalmol Clin, 50, 139, 10.1097/IIO.0b013e3181c551da Henderson, 2007, Clinical pseudophakic cystoid macular edema; risk factors for development and duration after treatment, J Cataract Refract Surg, 33, 1550, 10.1016/j.jcrs.2007.05.013 Levin, 2002, Update on pseudophakic cystoid macular edema treatment options, Ophthalmol Clin North Am, 15, 467, 10.1016/S0896-1549(02)00041-X Lincoff, 1996, Choroidal concentration of interferonafter retrobulbar injection, Invest Ophthalmol Vis Sci, 37, 2768 Sadowska-Bartosz, 2014, Oxidative modification of blood serum proteins in multiple sclerosis after interferon or mitoxantrone treatment, J Neuroimmunol, 266, 67, 10.1016/j.jneuroim.2013.11.005 Butler, 2012, Interferon alpha 2b in the treatment of uveitic cystoid macular edema, Ocul Immunol Inflamm, 20, 86, 10.3109/09273948.2011.645989 Deuter, 2011, Successful treatment of chronic pseudophakic macular edema(Irvine-Gass syndrome)with interferon alpha;a report of three cases, Ocul Immunol Inflamm, 19, 216, 10.3109/09273948.2011.562341 Maleki, 2018, Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema, Am J Ophthalmol Case Rep, 10, 203, 10.1016/j.ajoc.2018.03.005 Arcieri, 2005, Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial, Arch Ophthalmol, 123, 186, 10.1001/archopht.123.2.186 Kawali, 2021, Topical interferon– A novel treatment for pseudophakic macular edema, Indian J Ophthalmol, 69, 2355, 10.4103/ijo.IJO_2704_20 Bayyat, 2019, Update on pharmacotherapy for ocular surface squamous neoplasia, Eye Vis (Lond)., 6, 24, 10.1186/s40662-019-0150-5 Karp, 2010, Subconjunctival/perilesional recombinant interferon alpha2b for ocular surface squamous neoplasia: a 10-year review, Ophthalmology, 117, 2241, 10.1016/j.ophtha.2010.03.052